ERBB2 and neoplasm: An anti-HER-2 monoclonal antibody used to treat breast cancer, trastuzumab, was discovered to make HER-2-positive tumor cells more vulnerable to antibody-dependent and T cell-mediated cytotoxicity [111,112].